2023
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
Bowers J, Anna J, Bair S, Annunzio K, Epperla N, Pullukkara J, Gaballa S, Spinner M, Li S, Messmer M, Nguyen J, Ayers E, Wagner C, Hu B, Di M, Huntington S, Furqan F, Shah N, Chen C, Ballard H, Hughes M, Chong E, Nasta S, Barta S, Landsburg D, Svoboda J. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood Advances 2023, 7: 6630-6638. PMID: 37595053, PMCID: PMC10628810, DOI: 10.1182/bloodadvances.2023010622.Peer-Reviewed Original ResearchConceptsProgression-free survivalClassical Hodgkin lymphomaPeripheral neuropathyNontrial settingHodgkin's lymphomaTwo-year progression-free survivalTreatment-limiting side effectsInferior progression-free survivalECHELON-1 trialExperienced grade 1Multisite retrospective studyAdvanced-stage patientsDiscontinuation ratesOverall survivalPerformance statusFrontline treatmentRetrospective studyClinical trialsMultisite cohortIneligibility criteriaDose reductionHigh incidenceSide effectsPatientsGrade 1Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.
Bowers J, Anna J, Bair S, Annunzio K, Epperla N, Joy Pullukkara J, Gaballa S, Spinner M, Li S, Messmer M, Nguyen J, Ayers E, Wagner C, Hu B, Di M, Huntington S, Furqan F, Shah N, Chen C, Svoboda J. Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort. Journal Of Clinical Oncology 2023, 41: 7542-7542. DOI: 10.1200/jco.2023.41.16_suppl.7542.Peer-Reviewed Original ResearchProgression-free survivalClassic Hodgkin lymphomaECHELON-1 trialBrentuximab vedotinPeripheral neuropathyNon-trial settingOverall survivalLast followInferior progression-free survivalCox proportional hazards modelExperienced grade 1Grade peripheral neuropathyMulti-institution cohortEffect of discontinuationKaplan-Meier methodAdvanced-stage patientsMultivariable logistic regressionProportional hazards modelHigher initial doseDose holdsCommon toxicitiesMedian followDiscontinuation ratesPerformance statusMedian age
2022
Landscape of tumor genetic testing and targeted therapies over an eight-year span in a rural population.
Williams C, Guin S, Elsey R, Meißner T, Xu B, Sun Y, Amallraja A, Jun T, Schadt E, Chen R, Zhou X, Higashi M, Lee J, Oh W. Landscape of tumor genetic testing and targeted therapies over an eight-year span in a rural population. Journal Of Clinical Oncology 2022, 40: e15036-e15036. DOI: 10.1200/jco.2022.40.16_suppl.e15036.Peer-Reviewed Original ResearchAdvanced breast cancer patientsBreast cancer patientsTargeted therapyTargetable mutationsCancer patientsElectronic medical recordsNCCN guidelinesLabel useBRCA1/2 mutationsStage IIITumor typesNon-small cell lung cancerAdvanced prostate cancer patientsKRAS/NRAS mutationsReal-world patient populationPositive NGS resultsAdvanced breast cancerNGS resultsAdvanced-stage patientsCell lung cancerBRAF V600 mutationTumor molecular profilingProstate cancer patientsTumor genetic testingMolecular tumor board
2015
Improved prognosis for patients with oral cavity squamous cell carcinoma: Analysis of the National Cancer Database 1998–2006
Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity squamous cell carcinoma: Analysis of the National Cancer Database 1998–2006. Oral Oncology 2015, 52: 45-51. PMID: 26553389, DOI: 10.1016/j.oraloncology.2015.10.012.Peer-Reviewed Original ResearchConceptsOral cavity squamous cell carcinomaLate-stage diseaseThree-year overall survivalEarly-stage diseaseEarly-stage patientsStage diseaseSquamous cell carcinomaStage patientsNeck dissectionOverall survivalCell carcinomaObserved survival improvementNational Cancer DatabaseRetrospective cohort studyHigh-volume centersNegative surgical marginsAdvanced-stage patientsLarge administrative databaseAdjuvant chemoradiationOCSCC patientsAdjuvant therapyCohort studyImproved survivalSurgical marginsSurvival improvementCutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal Of Clinical Oncology 2015, 33: 3766-3773. PMID: 26438120, PMCID: PMC4979132, DOI: 10.1200/jco.2015.61.7142.Peer-Reviewed Original ResearchConceptsMF/Sézary syndromeAdvanced-stage MF/Sézary syndromeMedian overall survivalSézary syndromeIndependent prognostic markerOverall survivalPrognostic markerWorse survivalMycosis fungoidesAdvanced MF/SSSurvival rateAdvanced-stage mycosis fungoidesIdentical T-cell clonesStage IIB diseaseStage III diseaseStage IV diseaseSingle-center trialAdvanced-stage patientsIndependent prognostic valueSerum lactate dehydrogenasePrognostic index modelSpecific prognostic markersLarge cell transformationT cell clonesIIB diseaseHodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.
Montanari F, Diefenbach CS. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy. Clinical Advances In Hematology And Oncology 2015, 13: 518-24. PMID: 26351815.Peer-Reviewed Original ResearchConceptsClassical Hodgkin lymphomaCHL microenvironmentAutologous stem cell transplantLong-term disease controlTumor microenvironmentHeterogeneous inflammatory infiltratesReed-Sternberg (HRS) tumor cellsFirst-line therapyStem cell transplantAdvanced-stage patientsNew biologic insightsRelapsed patientsCell transplantInflammatory infiltrateHodgkin's lymphomaClinical trialsTherapeutic strategiesTumor growthTumor cellularityDisease controlNovel antitumor strategyBiologic insightsHRS cellsTumor cellsAntitumor strategyTreatment complexity: a description of chemotherapy and supportive care treatment visits in patients with advanced-stage cancer diagnoses
Sumpio C, Knobf MT, Jeon S. Treatment complexity: a description of chemotherapy and supportive care treatment visits in patients with advanced-stage cancer diagnoses. Supportive Care In Cancer 2015, 24: 285-293. PMID: 26026977, DOI: 10.1007/s00520-015-2775-9.Peer-Reviewed Original ResearchConceptsSC visitsVisit typeYoung subjectsTotal visitsAdvanced-stage cancer diagnosisTreatment complexityMethodsElectronic medical recordsTerms of chemotherapyAdvanced-stage patientsMore hoursMore total visitsChemotherapy visitsLung subjectsChemotherapy regimensCare visitsOlder patientsSupportive careYounger patientsTreatment visitsOutpatient infusionsCancer patientsMedical recordsTreatment periodAdditional visitsStage III
2011
Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression
Varughese J, Hui P, Lu L, Yu H, Schwartz PE. Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression. Journal Of Oncology 2011, 2011: 628084. PMID: 22187554, PMCID: PMC3236522, DOI: 10.1155/2011/628084.Peer-Reviewed Original ResearchProgression-free survivalClear cell cancerOverall survivalCell cancerUterine cancerAggressive histologic subtypeRetrospective chart reviewSingle institution experiencePlatinum-based chemotherapyAdvanced-stage patientsSingle academic institutionAdjuvant therapyChart reviewFIGO stageWorse survivalUterine corpusClinicopathologic featuresHistologic subtypePoor prognosisTreatment regimensExcellent survivalDisease progressionTreatment strategiesClinicopathologic parametersInnovative therapies
2010
Genetic alterations in malignant melanoma
Held M, Bosenberg M. Genetic alterations in malignant melanoma. Diagnostic Histopathology 2010, 16: 317-320. DOI: 10.1016/j.mpdhp.2010.03.001.Peer-Reviewed Original Research
2009
Rituximab Does Not Improve Progression Free (PFS) or Overall Survival (OS) in Patients with Limited Stage Diffuse Large B Cell Lymphoma (DLBCL).
Hochberg E, Birrer N, Toomey C, Barnes J, Lee A, LaCasce A, Abramson J. Rituximab Does Not Improve Progression Free (PFS) or Overall Survival (OS) in Patients with Limited Stage Diffuse Large B Cell Lymphoma (DLBCL). Blood 2009, 114: 3755. DOI: 10.1182/blood.v114.22.3755.3755.Peer-Reviewed Original ResearchLimited stage diffuse large B-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaUse of rituximabOverall survivalB-cell lymphomaSpeakers bureauCell lymphomaYounger low-risk patientsPrimary diffuse large B-cell lymphomaDana-Farber Cancer InstituteBenefit of rituximabGood-prognosis populationMultiple retrospective analysesAnthracycline-containing chemotherapyOverall survival benefitPatients 18 yearsLow-risk patientsAdvanced-stage patientsCD20 monoclonal antibodyLarge multicenter trialsTumor registry dataYears of ageMassachusetts General HospitalCurative intent
2006
Survival and toxicity differences between 5‐day and weekly cisplatin in patients with locally advanced cervical cancer
Einstein MH, Novetsky AP, Garg M, Hailpern SM, Huang GS, Glueck A, Fields AL, Kalnicki S, Goldberg GL. Survival and toxicity differences between 5‐day and weekly cisplatin in patients with locally advanced cervical cancer. Cancer 2006, 109: 48-53. PMID: 17123270, DOI: 10.1002/cncr.22369.Peer-Reviewed Original ResearchConceptsProgression-free survivalAdvanced cervical cancerCervical cancerWeekly groupWeekly CDDPAdvanced stage cervical cancerAdvanced-stage patientsCompletion of treatmentTimes higher riskExternal beam radiotherapyAcute toxicitySignificant demographic differencesOutpatient regimenWeekly cisplatinWeekly regimenConsecutive patientsTreatment failureSingle institutionDay concomitantBeam radiotherapyHigh riskRate brachytherapy treatmentPatientsRegimenRadiotherapy
2003
Overview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic Approaches
Foss F. Overview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic Approaches. Leukemia & Lymphoma 2003, 44: s55-s61. PMID: 15202526, DOI: 10.1080/10428190310001623757.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaNovel agentsTherapeutic approachesAcute T-cell leukemia/lymphomaAdvanced refractory cutaneous T cell lymphomasEarly-stage cutaneous T-cell lymphomaMycosis fungoides/Sézary syndromeRefractory cutaneous T-cell lymphomaPeripheral T-cell lymphomaAllogeneic stem cell therapyT-cell leukemia/lymphomaDemonstrated survival benefitYear of diagnosisAdvanced-stage patientsCytokine receptor antagonistsProbability of progressionNovel therapeutic approachesLeukemia/lymphomaNew therapeutic approachesNF-kappaB inhibitorHistone deacetylase inhibitorsStem cell therapyCytotoxic regimensExtracutaneous disease
1997
Patterns of Care for Cancer of the Larynx in the United States
Shah J, Karnell L, Hoffman H, Ariyan S, Brown G, Fee W, Glass A, Goepfert H, Ossoff R, Fremgen A. Patterns of Care for Cancer of the Larynx in the United States. JAMA Otolaryngology - Head & Neck Surgery 1997, 123: 475-483. PMID: 9158393, DOI: 10.1001/archotol.1997.01900050021002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdvanced-stage patientsRadiation therapyRegional metastasesLaryngeal cancerStage IIIDisease-specific survival outcomesFive-year survival rateStage IV diseaseAmerican Joint CommitteeEarly-stage patientsSeries of patientsSquamous cell carcinomaPatterns of careCase-mix characteristicsRadiochemotherapy protocolHospital recordsN classificationNonsurgical treatmentTreatment patternsSurvival outcomesCell carcinomaTreatment characteristicsLarge seriesPatientsUS hospitals
1986
Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up.
Winkler C, Sausville E, Ihde D, Fischmann A, Schechter G, Kumar P, Nibhanupdi J, Minna J, Makuch R, Eddy J. Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up. Journal Of Clinical Oncology 1986, 4: 1094-100. PMID: 3088220, DOI: 10.1200/jco.1986.4.7.1094.Peer-Reviewed Original ResearchConceptsTotal skin electron beam irradiationStage I patientsCutaneous T-cell lymphomaDisease-free survivalT-cell lymphomaI patientsStage IIComplete responseModality treatmentCell lymphomaStage IMedian disease-free survivalDisease-free survivorsThree-drug regimensCombined modality treatmentAdvanced-stage patientsOverall response rateOral corticosteroidsAdvanced diseaseSystemic chemotherapyProtocol treatmentTopical therapyStage patientsCR rateSimultaneous chemotherapy
1982
Malignant lymphoma I. The histology and staging of 473 patients at the national cancer institute
Anderson T, Chabner B, Young R, Berard C, Garvin AJ, Simon R, Devita V. Malignant lymphoma I. The histology and staging of 473 patients at the national cancer institute. Cancer 1982, 50: 2699-2707. PMID: 7139563, DOI: 10.1002/1097-0142(19821215)50:12<2699::aid-cncr2820501202>3.0.co;2-a.Peer-Reviewed Original ResearchConceptsDiffuse lymphoma patientsNodular lymphoma patientsLymphoma patientsNational Cancer InstituteDiffuse lymphomaCancer InstituteCS III diseaseAdvanced-stage patientsBurkitt's lymphoma patientsExtranodal diseaseClinical stagingConsecutive patientsMedian agePathologic stagingStage patientsRetrospective reviewMalignant lymphomaNodular lymphomaSystemic symptomsRappaport systemPathologic materialBurkitt's lymphomaPatientsLymphomaDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply